Dr. Neul is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3601 21st Ave S
Nashville, TN 37232Phone+1 615-322-3000
Education & Training
- Baylor College of MedicineResidency, Child Neurology, 2000 - 2005
- Baylor College of MedicineFellowship, Child Neurology, 2001 - 2004
- Baylor College of MedicineInternship, Transitional Year, 2000 - 2001
- University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2000
Certifications & Licensure
- TN State Medical License 2018 - 2025
- TX State Medical License 2006 - 2025
- CA State Medical License 2014 - 2022
- American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology
Awards, Honors, & Recognition
- Circle of Angels award for dedication to research on Rett syndrome International Rett Syndrome Foundation, 2011
- Philip R. Dodge Young Investigator Award Child Neurology Society, 2009
Clinical Trials
- Genetic and Physical Characteristics of Rett Syndrome Start of enrollment: 2006 Mar 01
- A Safety Study of NNZ-2566 in Patients With Rett Syndrome Start of enrollment: 2013 Mar 01
- A Safety Study of NNZ-2566 in Pediatric Rett Syndrome Start of enrollment: 2016 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 107 citationsRett Syndrome: A Prototypical Neurodevelopmental DisorderJeffrey L. Neul, Huda Y. Zoghbi
The Neuroscientist. 2004-04-01 - 851 citationsDysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypesHsiao-Tuan Chao, Hongmei Chen, Rodney C. Samaco, Mingshan Xue, Maria H. Chahrour
Nature. 2010-11-11 - 21 citationsRett Syndrome andDuplication Syndrome: Disorders of MeCP2 Dosage.Bridget E Collins, Jeffrey L Neul
Neuropsychiatric Disease and Treatment. 2022-01-01
Press Mentions
- First Treatment Approved for Rare Genetic Neurologic DisorderMarch 13th, 2023
- Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (Trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and OlderMarch 11th, 2023
- Trofinetide Shows Promise in Rett SyndromeApril 6th, 2022
- Join now to see all
Grant Support
- Rett Syndrome, MECP2 Duplications, and Rett-related Disorders Natural HistoryEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)2014–Present
- Baylor Intellectual and Developmental Disabilities Research CentersEEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)2014–Present
- Identification of Genetic Modifiers in Rett Syndrome.Rett Syndrome Research Trust2013–Present
- NNZ-2566 in Adult Rett SyndromeNeuren Pharmaceuticals2012–Present
- A randomized, double-blind placebo controlled trial of NNZ-2566 (IGF-1{1-3}, glycyl-L-2-methylprolyl-L-glutamine acid) with open label extension in adults with Rett syndromeInternational Rett Syndrome Foundation2012–Present
- Nonsense suppression as a therapeutic approach to Rett syndromeInternational Rett Syndrome Foundation2012–Present
- Creation of a DNA repository for Rett syndromeInternational Rett Syndrome Foundation2012–2014
- Characterization Of Autonomic Dysfunction In Rett Syndrome And Other MECP2 DisordEunice Kennedy Shriver National Institute Of Child Health &Human Development2010–2012
- Analysis Of The Dopamine System In Rett SyndromeNational Institute Of Neurological Disorders And Stroke2005–2009
Professional Memberships
- Member
- Child Neurology SocietyMember
Industry Relationships
- Consultant, TakedaAdvise on design of clinical trials in neurodevelopmental disorders
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: